PACIFIC BIOSCIENCES OF CALIFORNIA, INC.(PACB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,830 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PACB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB), a Technology sector company. 13F Pro's AI-powered ranking engine scores PACB at 17.1/100 on a 32-signal composite quality model, placing it at rank #2,830 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (5.4) and free cash flow (7.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reports quarterly revenue of $39.0M, net income of $-44.7M, free cash flow of $-37.1M. Top institutional holders of PACB by reported 13-F value include BlackRock, ARK Investment Management, SOFTBANK GROUP, based on the most recent SEC filings. PACB trades on the Nasdaq exchange and files with the SEC under CIK 1299130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PACB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. directly from SEC EDGAR. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s 13F Pro composite quality score has ranged between 13 and 18 since 2026, currently 17.1 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$39.0M
Net Income
Q2 2026
$-44.7M
Free Cash Flow
Q2 2026
$-37.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+3.9% YoYNet Income
-76.3% YoYOperating Income
-16.8% YoYEPS (Diluted)
-14.5% YoYTotal Assets
-37.8% YoYTotal Debt
Op. Cash Flow
+46.0% YoYFree Cash Flow
+46.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $160.0M +3.9% | $154.0M -23.2% | $200.5M +56.3% | $128.3M -1.7% | $130.5M +65.4% | $78.9M |
| Net Income | $-546.4M -76.3% | $-309.9M -1.0% | $-306.7M +2.4% | $-314.2M -73.4% | $-181.2M -716.3% | $29.4M |
| Operating Income | $-553.9M -16.8% | $-474.3M -41.8% | $-334.5M -8.9% | $-307.2M -46.0% | $-210.4M -101.6% | $-104.4M |
| EPS (Diluted) | $-1.82 -14.5% | $-1.59 -31.4% | $-1.21 +13.6% | $-1.40 -57.3% | $-0.89 -623.5% | $0.17 |
| Total Assets | $784.1M -37.8% | $1.26B -27.8% | $1.75B -1.2% | $1.77B -12.0% | $2.01B +384.8% | $414.0M |
| Total Debt | — | $0.00 -100.0% | $490.0K -99.9% | $898.5M +0.1% | $897.7M | — |
| Operating Cash Flow | $-111.2M +46.0% | $-206.1M +20.5% | $-259.2M +1.5% | $-263.2M -136.7% | $-111.2M -670.1% | $19.5M |
| Free Cash Flow | $-113.9M +46.3% | $-212.2M +20.8% | $-268.0M +4.3% | $-280.0M -139.1% | $-117.1M -734.3% | $18.5M |
Get alerted when PACB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. including:
Top Institutional Holders of PACB
BlackRock, Inc.
$54.3M32,339,550 shARK Investment Management LLC
$50.0M29,781,416 shSOFTBANK GROUP CORP.
$34.4M20,451,570 shVANGUARD CAPITAL MANAGEMENT LLC
$22.5M13,397,934 shGEODE CAPITAL MANAGEMENT, LLC
$12.8M7,606,518 shSumitomo Mitsui Trust Holdings, Inc.
$10.1M6,009,715 shNikko Asset Management Americas, Inc.
$10.0M6,009,715 shSTATE STREET CORP
$10.0M5,961,175 shPoint72 Asset Management, L.P.
$8.0M4,787,300 shTWO SIGMA INVESTMENTS, LP
$7.1M4,242,599 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $54.3M | 32,339,550 |
| ARK Investment Management LLC | $50.0M | 29,781,416 |
| SOFTBANK GROUP CORP. | $34.4M | 20,451,570 |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.5M | 13,397,934 |
| GEODE CAPITAL MANAGEMENT, LLC | $12.8M | 7,606,518 |
| Sumitomo Mitsui Trust Holdings, Inc. | $10.1M | 6,009,715 |
| Nikko Asset Management Americas, Inc. | $10.0M | 6,009,715 |
| STATE STREET CORP | $10.0M | 5,961,175 |
| Point72 Asset Management, L.P. | $8.0M | 4,787,300 |
| TWO SIGMA INVESTMENTS, LP | $7.1M | 4,242,599 |
Companies Similar to PACB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Cytek Biosciences, Inc.
Nano Dimension Ltd.
Quantum-Si Inc
Bionano Genomics, Inc.
Seer, Inc.
BigBear.ai Holdings, Inc.
indie Semiconductor, Inc.
Veritone, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Technology Companies
View all Technology →Put PACB on your watchlist
Track score changes the day PACIFIC BIOSCIENCES OF CALIFORNIA, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PACB a good stock to buy?
13F Pro's AI-powered analysis of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PACB are available on the PACB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PACB is classified as a small company.
Which hedge funds own PACB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PACB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s investment landscape.